Vaccination of mice with a modified Vaccinia Ankara (MVA) virus expressing the African horse sickness virus (AHSV) capsid protein VP2 induces virus neutralising antibodies that con...

by Calvo-Pinilla, E., de la Poza, F., Gubbins, S., Mertens, P. P. C., Ortego, J., Castillo-Olivares, J.
Published 2014

Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48 h before, or 48...

by Calvo-Pinilla, E., De La Poza, F., Gubbins, S., Mertens, P. P. C., Ortego, J., Castillo-Olivares, J.
Published 2015

Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48 h before, or 48...

by Calvo Pinilla, Eva María, De La Poza, F., Gubbins, S., Mertens, P. P. C., Ortego Alonso, Francisco Javier, Castillo-Olivares, J.
Published 2015

Vaccination of mice with a modified Vaccinia Ankara (MVA) virus expressing the African horse sickness virus (AHSV) capsid protein VP2 induces virus neutralising antibodies that con...

by Calvo Pinilla, Eva María, de la Poza, F., Gubbins, S., Mertens, P. P. C., Ortego Alonso, Francisco Javier, Castillo-Olivares, J.
Published 2014

A Modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR 2/2 mouse model

by Castillo-Olivares, J., Calvo-Pinilla, E., Casanova, I., Bachanek-Bankowska, K., Chiam, R., Maan, S., Nieto, J. M., Ortego, J., Mertens, P. P. C.
Published 2011

A Modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR 2/2 mouse model

by Castillo-Olivares, J., Calvo Pinilla, Eva María, Casanova, I., Bachanek-Bankowska, K., Chiam, R., Maan, S., Nieto, J. M., Ortego Alonso, Francisco Javier, Mertens, P. P. C.
Published 2011

Protection of IFNAR (-/-) mice against Bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2

by Jabbar, T. K., Calvo-Pinilla, E., Mateos, F., Gubbins, S., Bin-Tarif, A., Bachanek-Bankowska, K., Alpar, O., Ortego, J., Takamatsu, H. H., Mertens, P. P. C., Castillo-Olivares, J.
Published 2013

Protection of IFNAR (-/-) mice against Bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2

by Jabbar, T. K., Calvo Pinilla, Eva María, Mateos, F., Gubbins, S., Bin-Tarif, A., Bachanek-Bankowska, K., Alpar, O., Ortego Alonso, Francisco Javier, Takamatsu, H. H., Mertens, P. P. C., Castillo-Olivares, J.
Published 2013

Full Genome Characterisation of Bluetonge Virus Seroptype 6 from the Netherlands 2008 and Comparison to Other Field and Vaccine Strains

by Maan, S., Maan, N.S., van Rijn, P.A., van Gennip, H.G.P., Sanders, A.A., Wright, I.M., Batten, C., Hoffmann, B., Eschbaumer, M., Oura, C.A.L., Potgieter, C., Nomikou, K., Mertens, P.P.C.

Sequence analysis of bluetongue virus serotype 8 from the Netherlands 2006 and comparison to other European strains

by Maan, S., Maan, N.S., Ross-Smith, N., Batten, C., Shaw, A.E., Anthony, S., Samual, A.R., Darpel, K.E., Veronesi, E., Oura, C.A.L., Singh, K.P., Nomikou, K., Potgieter, A., Attoui, H., van Rooij, E.M.A., van Rijn, P.A., Clercq, K., Vandenbussche, F., Zientara, S., Breard, E., Sailleau, C., Beer, M., Hoffmann, B., Mellor, P.S., Mertens, P.P.C.